MicroRNA: Potential for Cancer Detection, Diagnosis, and Prognosis

Tricoli, James V.; Jacobson, James W.

doi:10.1158/0008-5472.can-07-0563

Cited by 204 publications

(134 citation statements)

References 0 publications

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…This cancer biology aspect of miRNA has been the subject of multiple recent reviews. 3,5,[28][29][30][31][32][33][34][35][36][37][38] In thyroid tumors, miRNA changes have been found in papillary thyroid carcinoma, 21,22,39 follicular carcinoma, 19 and anaplastic carcinoma. 20 In anaplastic carcinoma, the main changes appeared to be underexpression, and a significant decrease of miR-30d, miR-125b, miR-26a, and miR-30a-5p expression was described in comparison to normal thyroid tissue.…”

mentioning

confidence: 99%

MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma

et al. 2008

View full text Add to dashboard Cite

MicroRNA (miRNA) microarray analysis has consistently found altered expression of miRNAs in thyroid tumors, suggesting their roles in thyroid carcinogenesis. To explore whether this differential expression can be used as a diagnostic tool in surgical pathology and fine-needle aspirate (FNA) specimens, the expression of selected miRNA was evaluated by quantitative RT-PCR, using total RNA from 84 formalin-fixed paraffin-embedded tissues and 40 ex vivo aspirate specimens. miRNA from all paraffin-embedded tissues and all but one FNA sample were found to be analyzable, with paraffin sections yielding better miRNA quality. Preliminary analysis of 6 miRNAs in 10 papillary thyroid carcinoma and 10 follicular adenoma identified significant overexpression of miR-146b, -221, and -222 in papillary thyroid carcinoma (Po0.02), but not miR-146a, -155, or -187 (P40.08). The expression of these first three miRNAs was examined in a series of 5 normal thyroid, 11 hyperplastic nodules, 24 follicular adenoma, 27 classical papillary thyroid carcinoma, 5 follicular variant papillary thyroid carcinoma, 2 follicular carcinoma, and 10 encapsulated follicular lesions with partial nuclear features of papillary carcinoma. Results showed miR-146b to be most consistently overexpressed in both classical papillary carcinoma and follicular variants, whereas all other groups showed lower expression at a similar level (Po0.001 for pair-wise comparisons between papillary carcinoma and all other groups). Follicular lesions with partial features of papillary carcinoma all showed low miR-146b levels similar to other non-papillary carcinoma groups, suggesting that they are biologically distinctive from papillary carcinoma. miR-221 and miR-222 also showed higher expression in papillary carcinoma, but with substantial overlaps with the other groups. When applied to 40 FNA samples of various lesions, only miR-146b and miR-222 persisted as distinguishing markers for papillary carcinoma. We concluded that miRNAs, particularly miR-146b, might potentially be adjunct markers for diagnosing papillary thyroid carcinoma in both FNA and surgical pathology specimens.

show abstract

mentioning

confidence: 99%

MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma

et al. 2008

View full text Add to dashboard Cite

show abstract

“…IC 50 value at 48 h was selected to investigate the effect of 1386A on the global expression levels of miRNAs in MCF-7 cells. miRNAs are an important class of gene regulators which have the potential to function as a diagnostic and prognostic tool for a variety of human cancers (19,23,40,41). They constitute a novel target system for cancer treatment, because miRNA may regulate the expression of several hundred target genes, including important tumor related genes (37).…”

Section: Discussionmentioning

confidence: 99%

Marine fungal metabolite 1386A alters the microRNA profile in MCF-7 breast cancer cells

Tang

Cheng

et al. 2011

Mol Med Report

View full text Add to dashboard Cite

“…Further studies are warranted to profile the relationship between miRNAs and the stage of PC for their clinical use as biomarkers. Profiling miRNA in serum or pancreatic juice collected by endoscopic retrograde cholangiopancreatography (ERCP) may be regarded as the best prospect for miRNA-based biomarker development [23,24].…”

Section: Biomarkersmentioning

confidence: 99%